This Funding Opportunity Announcement (FOA) solicits grant applications proposing research projects on the advanced development of emerging molecular and cellular analysis technologies and validation in an appropriate cancer-relevant biological system. An emerging technology is defined as one that has passed the pilot developmental stage and shows promise, but has not yet been significantly evaluated within the context of its intended use. If successful, these technologies would accelerate research in cancer biology, cancer treatment and diagnosis, early detection and screening, cancer control and epidemiology, and/or cancer health disparities. This FOA solicits R33 applications where proof-of-principle of the proposed technology or methodology has been established and supportive preliminary data are available. Projects proposed to this FOA should reflect the potential to produce a molecular analysis technology with a major impact in cancer-relevant research. Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued are not appropriate for this FOA and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
For more information, please visit: